Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

John Strickler, MD, introduces a panel of medical experts who will provide key insights for considerations in the 3L colorectal cancer treatment setting.

Arvind Dasari, MD, MS, illustrates pivotal points of emphasis in choosing the appropriate treatment strategy for a patient receiving 3L treatment for colorectal cancer.

Medical experts dissect the first patient-specific case and corresponding treatment regimen.

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.